Venlo, the Netherlands, June 05, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy ...
QIAGEN N.V. QGEN recently announced the expansion of its digital PCR (dPCR) offering for the biopharma sector's cell and gene therapy development in partnership with Niba Labs. The recent development ...
Venlo, the Netherlands, Sept. 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (QGEN) (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAcuityDx Digital PCR System, a pivotal ...
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system ...
QIAGEN N.V. QGEN recently launched its QIAcuityDx Digital PCR System, whose instrument and accessories are Food and Drug Administration (“FDA”) 510(k) approved and In Vitro Diagnostic Regulation ...
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 ...
Venlo, the Netherlands, Nov. 09, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of three new kits for use on its QIAcuity systems and a major ...
Venlo, the Netherlands, July 18, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the expansion of its digital PCR (dPCR) offering for the development of ...
Qiagen N.V. (NYSE:QGEN) is one of the 10 potential takeover targets with strong price momentum. The latest relevant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results